MOLCURE Inc. today announced that it has signed a joint research agreement with FUJIFILM Corporation to advance peptide drug discovery technology using MOLCURE’s proprietary AI-powered drug discovery platform.
Under this agreement, MOLCURE’s proprietary AI drug discovery platform will be integrated with Fujifilm’s peptide discovery technology, which utilizes mRNA display methods to identify cyclic peptides containing unnatural amino acids with desired properties. By combining these technologies, the collaboration aims to further enhance the efficiency and performance of peptide discovery, accelerating the identification of peptides with higher binding affinity to target proteins.
“We are delighted that Fujifilm has recognized the value of MOLCURE’s AI drug discovery platform and entered into this joint research agreement,” said Satoshi Tamaki, CEO and CSO of MOLCURE. “We aim to enhance innovative peptide discovery technologies through this collaboration. We hope this partnership will lead to the discovery of novel therapeutics that improve patient outcomes and quality of life worldwide.”
About MOLCURE
MOLCURE Inc. is a leader in AI-driven drug discovery for antibodies and peptides. Our platform combines cutting-edge large language models (LLMs), physics-based simulations, and high-quality experimental data from our in-house labs. This approach enables the discovery of innovative biologics that are safer and more effective, making it possible to tackle undrugged targets that are challenging. We work with forward-thinking partners, including leading pharmaceutical companies, to accelerate R&D and help bring life-changing new treatments for patients around the world. Founded in 2013, MOLCURE is based in Japan, with headquarters in Kawasaki and a research facility in Tsuruoka. Learn more at https://molcure.com.
About Fujifilm’s Drug Discovery Support CRO Business
Fujifilm Group leverages its advanced AI technologies and biotechnological expertise, cultivated through a diverse range of business fields, to provide advanced and comprehensive solutions for full-scale drug discovery support CRO services to pharmaceutical companies and biotech ventures. These services span the discovery of new drug candidates to the evaluation of their efficacy and safety. We offer specialized peptide discovery services using mRNA display technology, as well as products from FUJIFILM Cellular Dynamics, Inc., a leading company in iPS cell technology. Guided by our “Partners for Life” principle, Fujifilm is committed to being a true partner to pharmaceutical companies and patients, contributing to the advancement of the pharmaceutical industry. For more details, please visit: https://global.fujifilm.com/en/healthcare-life-sciences/cro
For media and business inquiries:
Natsumi Negishi
MOLCURE Inc.
contact＠molcure.io
044-400-1894
